Maarouf Hoteit is a Gastroenterology physician affiliated with Hospital of the University of Pennsylvania. OpenAlex indexes 96 publications with 1,872 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Civic Center Blvd
Perelman Bldg - Gastroenterology
Philadelphia, PA 191044306
Telephone
215-349-8222Provider last certified this registry record 26 Oct 2021.
Clinical trials
- Cholate Clearance in Fontans
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Cook IncorporatedProgram year20251 payment
- Eisai Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
42.7%Beta blocker25.6%Carvedilol86%Nadolol14%Part D<11 patientsLoop diuretic10.9%Furosemide76%Bumetanide24%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
37.2%Proton pump inhibitor15.2%Omeprazole67%Lansoprazole33%Part D<11 patientsRifamycin Antibacterial9.7%Xifaxan100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
8.8%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor4.5%Entecavir100%Part D<11 patientsNucleoside and nucleotide reverse transcriptase inhibitors4.3%Vemlidy100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study
The American Journal of Gastroenterology
2025 - Liver Transplantation for Unresectable Colorectal Liver Metastases
Technology in Cancer Research & Treatment
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Mohamed Gad, MD, MPH
Hospital of the University of Pennsylvania
Lawrence Wechsler, MD
Hospital of the University of Pennsylvania
John Hirshfeld, MD
Hospital of the University of Pennsylvania
Noelle Frey, MD
Hospital of the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”